|
Lung Cancer
Clinical Research
Relapsed Small Cell Lung Cancer, Therapeutic
None at this time
Small Cell, Extensive Stage-Therapeutic
IRB# 207-07 Combination Cisplatin, Etoposide and Sunitinib Malate (IND 74019; NSC 736511) for Untreated Extensive Stage Small Cell Lung Cancer: A Phase IB/II Study (CALGB 30504)
Non-Small Cell Lung Cancer Stage I-Therapeutic
IRB# 367-07 A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm) -IIIA Non-Small Cell Lung Cancer (NSCLC) (E1505 - CTSU)
Stage I-Chemoprevention
None at this time.
Stage IIIA/IIIB-Therapeutic
IRB# 254-08 A Randomized Phase III Comparison of Standard-dose (60 Gy) Versus Highdose (74 Gy) Conformal Radiotherapy With Concurrent and Consolidation Carboplatin/Paclitaxel in Patients With Stage IIIA/IIIB Non-Small Cell Lung Cancer (CALGB 30609)
Advanced NSCLC, Therapeutic
IRB# 056-09 Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib (NSC #736511, IND # 74019) asS Maintenance Therapy in Non-Progressing Patients Following an Initial Four Cycles of Plantinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer (CALGB 30607)
IRB# 279-08 A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC #736511, IND #74019) or Pemetrexed plus Sunitinib in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer (CALGB 30704)
Last Updated: 01/20/2010
|